Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
IMPORTANCE: With the emergence of SARS-CoV-2 viral variants, there has been an increase in infections in vaccinated individuals. Here, we isolated monoclonal antibodies (mAbs) from individuals experiencing a breakthrough infection (Delta or BA.1) to determine how exposure to a heterologous Spike broadens the neutralizing antibody response at the monoclonal level. All mAbs isolated had reactivity to the Spike of the vaccine and infection variant. While many mAbs showed reduced neutralization of current circulating variants, we identified mAbs with broad and potent neutralization of BA.2.75.2, XBB, XBB.1.5, and BQ.1.1 indicating the presence of conserved epitopes on Spike. These results indicate that variant-based vaccine boosters have the potential to broaden the vaccine response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
mBio - 14(2023), 5 vom: 31. Okt., Seite e0120623 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seow, Jeffrey [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 01.05.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/mbio.01206-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362436258 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362436258 | ||
| 003 | DE-627 | ||
| 005 | 20240501232103.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/mbio.01206-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1394.xml |
| 035 | |a (DE-627)NLM362436258 | ||
| 035 | |a (NLM)37747187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seow, Jeffrey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 01.05.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IMPORTANCE: With the emergence of SARS-CoV-2 viral variants, there has been an increase in infections in vaccinated individuals. Here, we isolated monoclonal antibodies (mAbs) from individuals experiencing a breakthrough infection (Delta or BA.1) to determine how exposure to a heterologous Spike broadens the neutralizing antibody response at the monoclonal level. All mAbs isolated had reactivity to the Spike of the vaccine and infection variant. While many mAbs showed reduced neutralization of current circulating variants, we identified mAbs with broad and potent neutralization of BA.2.75.2, XBB, XBB.1.5, and BQ.1.1 indicating the presence of conserved epitopes on Spike. These results indicate that variant-based vaccine boosters have the potential to broaden the vaccine response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a immunization | |
| 650 | 4 | |a infectious disease | |
| 650 | 4 | |a monoclonal antibodies | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Shalim, Zayed A |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Kimuda, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Pillai, Aswin |e verfasserin |4 aut | |
| 700 | 1 | |a Lechmere, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Kurshan, Ashwini |e verfasserin |4 aut | |
| 700 | 1 | |a Khimji, Atika M |e verfasserin |4 aut | |
| 700 | 1 | |a Snell, Luke B |e verfasserin |4 aut | |
| 700 | 1 | |a Nebbia, Gaia |e verfasserin |4 aut | |
| 700 | 1 | |a Mant, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Waters, Anele |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Malim, Michael H |e verfasserin |4 aut | |
| 700 | 1 | |a Doores, Katie J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t mBio |d 2010 |g 14(2023), 5 vom: 31. Okt., Seite e0120623 |w (DE-627)NLM200128191 |x 2150-7511 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:5 |g day:31 |g month:10 |g pages:e0120623 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/mbio.01206-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 5 |b 31 |c 10 |h e0120623 | ||